Pharmaceutical company AIM ImmunoTech (NYSE American: AIM) has reported that it has received statistically significant positive pancreatic cancer survival results from its Early Access Program (EAP).
The program which was conducted at Erasmus University Medical Centre in the Netherlands found a “statistically significantly positive survival benefit when using Ampligen in patients with locally advanced/metastatic pancreatic cancer after systemic chemotherapy,” according to AIM’s press statement.
Professor Casper van Eijick MD PhD who led the program, said that “Median survival was approximately two-fold higher, that is 200%, in the Ampligen arm as compared to the historical controls.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
“These results were obtained with a very high degree of statistical significance. Based on these data, I see the potential for Ampligen as a meaningful extension of the standard of care for advanced pancreatic cancer, which we are planning to investigate further.”
AIM said they will now look for FDA “fast-track” and possibly FDA “breakthrough” designations to conduct Phase 2 and 3 trials both in the Netherlands and the US.
They also plan to file dual orphan drug status applications for the use of Ampligen with the FDA.
AIM shares…
AIM’s stock price jumped 22% higher after the news and is currently trading at $2.49 premarket after closing Monday’s session down 2% at $2.04.
Its share price has increased by 275% so far in 2020.
PEOPLE WHO READ THIS ALSO VIEWED:
